IXICO plc (GB:IXI) has released an update.
IXICO plc, a precision analytics firm specializing in neuroscience, has secured a long-term contract to provide imaging biomarker services for a Phase 1/2 Huntington’s Disease trial with a U.S. pharma client. The study is slated to last up to a decade and is expected to contribute approximately £2 million to IXICO’s order book. The company is recognized for its expertise in advanced imaging biomarkers, supporting the development of crucial treatments in neurological diseases.
For further insights into GB:IXI stock, check out TipRanks’ Stock Analysis page.
